Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on December 5, 2025, covering events reported as of December 1, 2025. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change disclosed is the appointment of David Hastings as Chief Financial Officer and principal financial officer, effective January 6, 2026. Mr. Hastings brings extensive experience from Arbutus Biopharma, Unilife Corporation, Incyte Corporation, and ArQule Inc.
Compensatory Arrangements and Outlook
- Base Salary: Annualized base salary of $522,000.
- Annual Incentive Bonus: Eligible for up to 40% of the annualized base salary.
- Equity Grant: Option to purchase 375,000 shares of common stock at the closing price on the grant date.
- Vesting Schedule: 25% vests on the first anniversary of the grant date; the remaining 75% vests monthly thereafter (1/48th per month).
- Separation Benefits: Eligible for benefits under the Company's Executive Separation Benefits and Retention Plan.
- Indemnification: The Company will enter into a standard indemnification agreement covering expenses, judgments, fines, and settlement amounts arising from his service.
The filing does not provide specific guidance, outlook, or risk factors beyond the standard indemnification obligations.
Investor Verification Checklist
- Verify the exact grant date and exercise price for the 375,000 stock options once the grant is executed.
- Review the full text of the Offer Letter when filed as an exhibit to the 2025 Form 10-K for complete terms.
- Confirm the effective start date of January 6, 2026, and any interim financial officer arrangements.
- Assess the impact of the new CFO's compensation package on the company's cash burn rate and future dilution.